Calpains

Introduction

Calpains is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes.

Overview

Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate [proteins](/proteins) in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking [amyloid-beta](/proteins/amyloid-beta) toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions ([Bhatt et al., 2012](https://doi.org/10.1159/000345523)). [@bhatt2008]

Calpain overactivation in AD operates through a devastating cascade: [Aβ](/proteins/amyloid-beta)-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating [CDK5](/genes/cdk5), degrade [PP2A](/entities/pp2a) (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD. [@bhatt2014]

Structure and Isoforms

Calpain Family

Introduction

Calpains is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes.

Overview

Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate [proteins](/proteins) in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking [amyloid-beta](/proteins/amyloid-beta) toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions ([Bhatt et al., 2012](https://doi.org/10.1159/000345523)). [@bhatt2008]

Calpain overactivation in AD operates through a devastating cascade: [Aβ](/proteins/amyloid-beta)-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating [CDK5](/genes/cdk5), degrade [PP2A](/entities/pp2a) (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD. [@bhatt2014]

Structure and Isoforms

Calpain Family

The human genome encodes 15 calpain isoforms. The two ubiquitous "classical" calpains are most relevant to neurodegeneration: [@lee2000]

| Isoform | Also Known As | Ca2+ Requirement | Brain Expression | Disease Relevance | [@goll2003]
|---------|---------------|-----------------|-----------------|-------------------| [@bhatt2009]
| Calpain-1 | μ-calpain | Micromolar (~3-50 μM) | Neurons] (synapses, cell body) | Synaptic plasticity; protective at physiological levels | [@bhatt2022]
| Calpain-2 | m-calpain | Millimolar (~0.4-0.8 mM) in vitro; lower in vivo due to regulation | [neurons](/entities/neurons), glia | Pathological; mediates excitotoxic damage | [@patrick1999]
| Calpain-5 | — | Unknown | Retina, brain | Retinal degeneration | [@bhatt2015]
| Calpain-10 | — | Unknown | Ubiquitous | Linked to type 2 diabetes susceptibility | [@wang2000]

Molecular Architecture

Classical calpains (calpain-1 and -2) are heterodimers: [@bhatt2013]

Large (catalytic) subunit (~80 kDa; CAPN1 or CAPN2):

• Domain I: N-terminal anchor helix
• Domain II (protease core): Cysteine protease catalytic domain (papain-like fold); divided into IIa and IIb subdomains containing the catalytic triad (Cys105, His262, Asn286)
• Domain III: C2-like domain; binds phospholipids and calcium
• Domain IV: Penta-EF-[hand](/diseases/hand) domain; binds calcium; mediates heterodimerization

• Domain V: Glycine-rich hydrophobic region
• Domain VI: Penta-EF-hand domain; dimerizes with domain IV

Activation Mechanism

Calpastatin: Endogenous Calpain Inhibitor

Calpastatin (encoded by CAST) is the only known endogenous specific inhibitor of classical calpains:

• Contains four inhibitory domains, each capable of inhibiting one calpain molecule
• Binds to calcium-activated calpain with extremely high affinity
• Calpastatin itself is a calpain substrate — creating a destructive feedback loop when calpain is overactivated
• Critical AD finding: Calpastatin is markedly depleted (~50-75%) in AD brain ([Bhatt et al., 2008](https://doi.org/10.1523/JNEUROSCI.2799-08.2008)), removing the brake on calpain activity
• Calpastatin overexpression in tau] P301L mice prevents tauopathy, tau] fragmentation, and neurodegeneration, and restores normal lifespan ([Bhatt et al., 2014](https://doi.org/10.1523/JNEUROSCI.4227-13.2014))

Role in Alzheimer's Disease

Calcium-Calpain Cascade

In AD, multiple sources of pathological calcium elevation drive calpain overactivation:

Calpain-CDK5/p25 Pathway

One of the most pathologically significant calpain substrates is p35, the regulatory activator of [CDK5](/genes/cdk5):

• Calpain also cleaves I2PP2A/SET, generating fragments that inhibit remaining [PP2A](/entities/pp2a)
• Net effect: ~50% reduction in [PP2A](/entities/pp2a) activity in AD brain
• Combined with [CDK5](/genes/cdk5)/p25 activation, this creates a kinase-phosphatase imbalance maximally favoring [tau](/proteins/tau) hyperphosphorylation]

Calpain-Mediated Tau Truncation

Calpains directly cleave tau](/proteins/tau at multiple sites:

• Generate truncated tau fragments (e.g., tau 17 kDa fragment) that are highly aggregation-prone
• Truncated tau acts as a seed for further tau oligomerization and tangle formation
• Calpain-generated tau fragments are found in NFTs in AD brain
• These fragments are more neurotoxic than full-length hyperphosphorylated tau

BACE1 Upregulation

• Calpain activation increases BACE1 expression and stability in [neurons](/entities/neurons)
• Mechanism involves calpain-mediated cleavage of the BACE1 translational repressor GGA3
• Increased BACE1 enhances [Aβ](/proteins/amyloid-beta) production, further driving calcium influx — a feed-forward loop

Synaptic Destruction

Calpain-mediated proteolysis of synaptic proteins drives cognitive decline:

| Substrate | Function | Consequence of Cleavage |
|-----------|----------|----------------------|
| αII-spectrin (fodrin) | Membrane cytoskeleton scaffold | Loss of dendritic spine structure; spectrin breakdown products (SBDPs) are biomarkers |
| PSD-95 | Postsynaptic scaffold | Disrupted receptor clustering and synaptic transmission |
| Homer1 | Postsynaptic scaffold | Impaired metabotropic [glutamate](/entities/glutamate) receptor signaling |
| [NMDA receptor](/entities/nmda-receptor)] receptor subunits | Excitatory receptor | Altered receptor function and trafficking |
| Dynamin-1 | Synaptic vesicle endocytosis | Impaired synaptic vesicle recycling |
| GAP-43 | Growth cone/synaptic plasticity | Reduced synaptic remodeling |

Apoptosis and Necrosis

Calpain activation contributes to neuronal death through multiple mechanisms:

• Cleavage of pro-caspase-3 → activation of caspase cascade → [apoptosis](/entities/apoptosis)
• Cleavage of Bid → truncated Bid (tBid) → mitochondrial cytochrome c release
• Degradation of Bcl-2 and Bcl-xL → loss of anti-apoptotic protection
• Cleavage of AIF (apoptosis-inducing factor) → caspase-independent cell death
• Calpain-caspase crosstalk: [caspases](/entities/caspases) also cleave calpastatin, further amplifying calpain activity

Calpain in Other Neurodegenerative Diseases

Parkinson's Disease

• [α-Synuclein](/proteins/alpha-synuclein) is a calpain substrate; truncated fragments promote aggregation
• Calpain-mediated cleavage of [Parkin](/proteins/parkin) reduces its E3 ligase activity
• [Dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in the [substantia nigra](/brain-regions/substantia-nigra) are particularly vulnerable to calcium-calpain damage

ALS

• [TDP-43](/proteins/tdp-43) is cleaved by calpains to generate aggregation-prone 25 kDa and 35 kDa fragments found in ALS inclusions
• [Motor neurons](/cell-types/motor-neurons) express high calpain-1 levels, increasing vulnerability

Huntington's Disease

• Mutant [huntingtin](/proteins/huntingtin) is cleaved by calpains, generating toxic N-terminal fragments
• Calpain-resistant [huntingtin](/proteins/huntingtin) mutants show reduced toxicity in models

Traumatic Brain Injury

• Acute calpain activation is a hallmark of TBI
• αII-spectrin breakdown products (SBDPs) in CSF and blood are established TBI biomarkers
• Chronic calpain activation after TBI may contribute to post-traumatic neurodegeneration (CTE)

Therapeutic Targeting

Calpain Inhibitors

| Compound | Mechanism | Status | Key Findings |
|----------|-----------|--------|-------------|
| SNJ-1945 (BLD-2660) | Reversible, brain-penetrant calpain inhibitor | Phase 1 | Reduces tau pathology] in AD mice; good oral bioavailability |
| PD150606 | Non-competitive calpain-1/2 inhibitor | Preclinical | Selectively inhibits calpains vs. cathepsins |
| MDL-28170 | Cell-permeable calpain inhibitor | Preclinical | Neuroprotective in [excitotoxicity](/entities/excitotoxicity) and ischemia models |
| E-64d | Broad cysteine protease inhibitor | Preclinical | Reduces [Aβ](/proteins/amyloid-beta) pathology; limited selectivity |

Calpastatin-Based Strategies

• Calpastatin [gene therapy](/therapeutics/gene-therapy): AAV-mediated CAST overexpression prevents tauopathy in mice and restores lifespan
• Calpastatin-mimetic peptides: Smaller peptides based on the inhibitory domain of calpastatin
• Calpastatin stabilization: Preventing calpain-mediated degradation of calpastatin

Upstream Calcium-Targeting Approaches

Rather than directly inhibiting calpains, targeting upstream calcium dysregulation:

• [NMDA receptor](/entities/nmda-receptor) receptor] antagonists ([memantine](/therapeutics/memantine) — FDA-approved for AD)
• [Ryanodine receptor](/entities/ryanodine-receptor) stabilizers (Rycal compounds)
• Voltage-gated calcium channel blockers
• Restoring ER calcium homeostasis

Biomarkers

Spectrin Breakdown Products (SBDPs)

• Calpain-generated αII-spectrin fragments (SBDP150, SBDP145) are detectable in CSF and blood
• Established biomarkers in TBI; under investigation for AD
• Distinguish calpain-mediated (SBDP145) from caspase-mediated (SBDP120) cleavage patterns

See Also

• [BACE1](/entities/bace1) ([Beta-Secretase

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
• [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data

Background

The study of Calpains has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration](/mechanisms) and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: [Calpains expression search](https://human.brain-map.org/microarray/search/show?search_term=Calpains)
• Allen Mouse Brain Atlas: [Calpains search](https://mouse.brain-map.org/search/index.html?query=Calpains)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Calpains developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Calpains)

References